To summarise, treatment with ASC-EVs tends to reduce the expression of ITGα5, ITGαV, ITGβ1, ITGβ3, and KDR genes, which could be essential for tumour cell invasion into CAM. This evidence concerns the gene ITGB1 and neoplasm.